Sylvie Grégoire is former president of Human Genetic Therapies Shire PLC, US and Switzerland from 2007 to 2013. Prior to that, she was executive chairman of IDM Pharma Inc., US, from 2006 to 2007, and president and chief executive officer in GlycoFi Inc., US from 2003 to 2004. From 1995 until 2003 Ms Grégoire held various leadership positions in Biogen, Inc., in France and the US, recently as executive vice president of Technical Operations. Prior to this, Ms Grégoire was at Merck and Co, in clinical research and regulatory affairs in Canada, US and Belgium for a period of 8 year prior. Ms Grégoire serves as chairman of the board of Corvidia Therapeutics Inc., US. Ms Grégoire also serves as executive chair of the board of Metriopharm, Switzerland. Further, Ms Grégoire serves as a member of the board of Galenica AG, Switzerland and of the board of Perkin Elmer Inc., US. Ms Grégoire has a Pharmacy Doctorate degree from the State University of NY at Buffalo, US, from 1986, a B.A. in Pharmacy from Laval University, Canada, from 1984 and a Science College degree from Seminaire de Sherbrooke, Canada, from 1980. Ms Grégoire was first elected to the Board of Novo Nordisk A/S in March 2015 and has recently been re-elected in 2017. Her term as a board member expires in March 2018.

She is having experience with all phases of the product life cycle, including discovery, registration, pre-launch and managing the life cycle while on the market. In addition, Ms Grégoire has financial insight including into P&L responsibility.